



PRESS RELEASE

31 MARCH 2015

11.30 PM CET

Cardio3 BioSciences announces intention to conduct a registered public offering in the United States

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced its intention to conduct a registered public offering in the United States. The timing, number of shares and price of the proposed offering have not yet been determined.

A draft registration statement relating to these securities has been confidentially submitted to the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement has been publicly filed and has become effective.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

*** END ***

For more information, please contact:

Cardio3 BioSciences

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

For Europe: Consilium Strategic Communications

Amber Bielecka, Chris Welsh, Laura Thornton

For the U.S: The Ruth Group

Lee Roth (Investors), Kirsten Thomas (Media)

www.c3bs.com

Tel: +32 10 39 41 00

jgrade@c3bs.com

Tel : +44 20 3709 5700

cardio3@consilium-comms.com

Tel: +1 646 536 7012 / 7014

lroth@theruthgroup.com

kthomas@theruthgroup.com

To subscribe to Cardio3 BioSciences' newsletter, visit www.c3bs.com.

Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

About Cardio3 BioSciences

Cardio3 BioSciences is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiovascular disease and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Company's lead product candidate in cardiology is C-Cure®, an autologous stem cell therapy for the treatment of ischemic heart failure. The Company's lead product candidate in oncology is CAR-NKG2D, an autologous CAR T-cell product candidate using NKG2D, a natural killer cell receptor designed to



PRESS RELEASE

31 MARCH 2015

11.30 PM CET

target ligands present on multiple tumor types, including ovarian, bladder, breast, lung and liver cancers, as well as leukemia, lymphoma and myeloma. Cardio3 BioSciences is also developing medical devices for enhancing the delivery of diagnostic and therapeutic agents into the heart (C-Cath_{ez}[®]) and potentially for the treatment of mitral valve defects.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

To learn more about Cardio3 BioSciences, please visit www.c3bs.com

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, including statements concerning the potential registered initial public offering, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure[®] and Phase I clinical trial for CAR-NKG2D additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and new business initiatives. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

C-Cure, CAR-NKG2D, C-Cath_{ez}, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath_{ez}, CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company.